LifeBridge Health Researchers Contribute to Development of First FDA Authorized AI Tool for Sepsis Diagnosis
Sinai Hospital was one of 10 research centers in the United States to be part of a groundbreaking study that supported development of an algorithm to guide the rapid diagnosis and prediction of sepsis in hospital patients. The Sepsis ImmunoScore™, the diagnostic tool developed by Prenosis, uses artificial intelligence in the detection of sepsis and received Food and Drug Administration authorization in April 2024.
Sepsis is a life-threatening condition that occurs when the body’s immune system has an extreme response to an infection, causing organ dysfunction. According to the World Health Organization, sepsis represents 20% of all global deaths, including 1.5% of hospital patients. The Centers for Disease Control and Prevention estimates that 1.7 million adults in the U.S. develop sepsis each year and at least 350,000 die during their hospitalization or are discharged to hospice care.
“The team at the Sinai Center for Thrombosis Research and Drug Development was fortunate to have been approached to collaborate on this important research and bring this work to Sinai Hospital. Based on our pioneering work in the biomarker arena for over two decades, Prenosis felt we would be a valuable partner. The tool that was developed from this work promises to save the lives of many,” says Paul Gurbel, M.D., director of the Sinai Center for Thrombosis Research and Drug Development at Sinai Hospital of Baltimore.
More than 10,000 blood samples from 2,000 Sinai patients contributed to support this study. These samples, part of 100,000 samples studied nationwide, led to the development of the first FDA-authorized artificial intelligence (AI) tool to detect sepsis developed by Prenosis, a Chicago-based artificial intelligence company specializing in precision medicine in acute care. The Sepsis ImmunoScore™ tool is integrated into hospital electronic medical records and analyzes 22 parameters to determine patterns in the human biologic response, detecting signs or likelihood of sepsis. This tool has the potential to enable treatment to begin earlier and, as a result, better fight infections and reduce harm to key organs like the lungs and liver.
“As researchers at LifeBridge Health, we are proud of our contribution to the first sepsis artificial intelligence algorithm authorized by the Food and Drug Administration. This achievement underscores our commitment to collaborative efforts aimed at advancing medical technology,” says Martin Gesheff, DHSc, executive director of the LifeBridge Health Department of Research.
"The Sepsis ImmunoScore™ is the first-ever FDA-authorized AI diagnostic tool for sepsis,” states Bobby Reddy, Jr, Ph.D., co-founder and CEO of Prenosis. “Sepsis, a long-standing challenge within the U.S. healthcare system, is notoriously difficult to diagnose. Early recognition and intervention are crucial for patient survival. The Sepsis ImmunoScore™ marks a significant advancement in delivering precision medicine solutions to providers in acute care settings. Our Sepsis ImmunoScore™ was built using Prenosis’ Immunix™ precision medicine platform, a solution enabling precision medicine in acute care. Immunix™ uses AI to extract deep biological insights, empowering the development and validation of new precision medicine tools and the real-time implementation of those tools to improve patient care and outcomes. We are honored to have LifeBridge Health as a participant in this pioneering research.”
About LifeBridge Health: LifeBridge Health is one of the largest, most comprehensive providers of health services in Maryland. LifeBridge Health includes Sinai Hospital, Northwest Hospital, Carroll Hospital, Levindale Hebrew Geriatric Center and Hospital, Grace Medical Center and related subsidiaries and affiliates. For more information, visit https://www.lifebridgehealth.org/
Contact: Theo Hayes, 410-601-2296, thayes3@lifebridgehealth.org